产品: KAT3B/p300 抗体
货号: AF5360
描述: Rabbit polyclonal antibody to KAT3B/p300
应用: WB IHC IF/ICC
文献验证: WB
反应: Human, Mouse, Rat
预测: Bovine, Horse, Sheep, Rabbit, Chicken, Xenopus
蛋白号: Q09472
RRID: AB_2837845

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
KAT3B / p300 Antibody detects endogenous levels of total KAT3B/p300.
RRID:
AB_2837845
引用格式: Affinity Biosciences Cat# AF5360, RRID:AB_2837845.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

E1A associated protein p300; E1A binding protein p300; E1A-associated protein p300; EP300; EP300: E1A binding protein p300; EP300_HUMAN; Histone acetyltransferase p300; KAT3B; p300 HAT; RSTS2;

抗原和靶标

免疫原:

A synthesized peptide derived from human KAT3B/p300, corresponding to a region within N-terminal amino acids.

基因/基因ID:
描述:
Functions as histone acetyltransferase and regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation. Mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein.

研究领域

· Cellular Processes > Cell growth and death > Cell cycle.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Adherens junction.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Wnt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Notch signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TGF-beta signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Human Diseases > Neurodegenerative diseases > Huntington's disease.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Organismal Systems > Nervous system > Long-term potentiation.

· Organismal Systems > Endocrine system > Melanogenesis.

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Glucagon signaling pathway.

文献引用

1). YY1 complex promotes Quaking expression via super-enhancer binding during EMT of hepatocellular carcinoma. CANCER RESEARCH, 2019 (PubMed: 30760518) [IF=12.5]

Application: WB    Species: human    Sample: PLC-PRF-5 cells

Fig. 7 |Hyperoside inhibits the EMT and metastasis of HCC by targeting YY1 complex.(a) Detailed binding mode of YY1, p65, and p300. (b) Prediction score of docking between small-molecule drugs and YY1 complex. (c) The structure of hyperoside (left). Predicted binding modes of hyperoside (green) and YY1/p65/p300 complex (right). (d) Co-IP of endogenous YY1, p65, and p300 was performed in PLC-PRF-5 cells treated with 120 µM hyperoside.

2). Enhanced glycolysis-derived lactate promotes microglial activation in Parkinson's disease via histone lactylation. NPJ Parkinson's disease, 2025 (PubMed: 39753581) [IF=8.7]

3). Musashi-2 potentiates colorectal cancer immune infiltration by regulating the post-translational modifications of HMGB1 to promote DCs maturation and migration. Cell communication and signaling : CCS, 2024 (PubMed: 38347600) [IF=8.4]

Application: WB    Species: human    Sample: MSI2 and EP300 in SW620 and LOVO cells

Fig. 4 From: Musashi-2 potentiates colorectal cancer immune infiltration by regulating the post-translational modifications of HMGB1 to promote DCs maturation and migration MSI2 interacts with P300 to promote K29-HMGB1 acetylation, translocation and extracellular release. A Western blot analysis of acetyllysine in stable SW620 and LOVO cells. B Identification of lysine acetylation at K29 and K30 of HMGB1 by 4D label-free acetylome sequencing in stable SW620 cells. C Four gene clusters (Q1-Q4) based on the fold difference were identified in stable SW620 cells. D KEGG pathway enrichment analysis of the gene clusters (Q1-Q4) by BP and MF. E The DEGs identified by proteomics in stable SW620 and LOVO cells were subjected to KEGG pathway enrichment analysis using the DAVID bioinformatics tool. F Acetyl-K29-HMGB1 expression in the extracellular supernatant of stable SW620 and LOVO cells treated with or without 10 μg/mL LPS for 8 h. G Representative IFC images showing aberrant low expression of Acetyl-K29-HMGB1 in SW620 and LOVO cells with stable MSI2 knockdown. Scale bars, 100 μm. H-I Ectopic nucleocytoplasmic translocation of Acetyl-K29-HMGB1 in stable SW620 and LOVO cells in the absence (H) or presence (I) of LPS (10 μg/mL) for 8 h. J Acetyl-K29-HMGB1 and HMGB1 protein levels in HEK 293 T, SW620 and LOVO cells treated with TSA (1 μM) or (and) NAM (10 mM) for 12 h. K IP of HMGB1 and acetyllysine in stable SW620 and LOVO cells. L Positive correlations between MSI2 expression and KATs and KDACs expression in TCGA CRC database. M Heatmap of MSI2 and KAT/KDACs protein expression in stable SW620 cells as determined by 4D label-free proteomics. N MSI2, HDAC1, HDAC2, SIRT1 and EP300 mRNA expression was measured by qRT–PCR in stable SW620 and LOVO cells cultured in the presence of LPS (10 μg/mL) for 8 h. O Endogenous Co-immunoprecipitation of MSI2 and EP300 in SW620 and LOVO cells. P Representative IFC images of MSI2 and EP300 cytoplasmic localization in SW620 and LOVO cells. Scale bars, 10 μm. Q Representative IHC images of P300 from CAC mice and statistical analysis for P300 average IHC staining density. Scale bars, 100 μm. R Western blot analysis of EP300, HMGB1, K29-HMGB1 and NF-κB gene expression in CAC mice and stable CRC cells. These results are presented as the mean ± SD values; ns: not significant, **p 

4). The mechanism of SP1/p300 complex promotes proliferation of multiple myeloma cells through regulating IQGAP1 transcription. BIOMEDICINE & PHARMACOTHERAPY, 2019 (PubMed: 31536933) [IF=6.9]

Application: WB    Species: human    Sample: myeloma cell

Fig. 2.| A. The mRNA expression level of IQGAP1 in myeloma cell lines among different group (Sp1-siRNA: p<0.0001; p300-siRNA: p = 0.0003;pcDNA3.1-Sp1: p<0.0001; pcDNA3.1- p300: p<0.0001). B. The mRNA expression level of Sp1 in myeloma cell lines among different group (Sp1-siRNA: p = 0.0014; pcDNA3.1-Sp1:p = 0.0001; pcDNA3.1- p300: p = 0.0006). C. The mRNA expression level of p300 in myeloma cell lines among different group (p300-siRNA: p = 0.0012; pcDNA3.1-Sp1: p = 0.0003; pcDNA3.1- p300: p = 0.0002). D. The protein level of Sp1, p300, IQGAP1, ERK1/2 and p-ERK1/2 in myeloma cell lines among different group.

5). β-Patchoulene Ameliorates Water Transport and the Mucus Barrier in 5-Fluorouracil-Induced Intestinal Mucositis Rats via the cAMP/PKA/CREB Signaling Pathway. Frontiers in Pharmacology, 2021 (PubMed: 34512326) [IF=5.6]

Application: WB    Species: Rat    Sample:

FIGURE 5 Effects of β-PAE on AQP3 expression and cAMP/PKA/CREB signaling pathway-related proteins. (A,B) AQP3 expression; (C,D) VIP, VIPR2, cAMP and PKA expression; (E,F) MEK1/2, p-MEK1/2, ERK, p-ERK, p-p38, p38, MSK1, p-MSK1, CREB, p-CREB, and P300/CBP expression. Data are shown as mean ± SD (n = 3). # p < 0.05, ## p < 0.01 versus control group; * p < 0.05, ** p < 0.01 versus 5-FU group.

6). Phlorizin, a novel caloric restriction mimetic, stimulates hypoxia and protects cardiomyocytes through activating autophagy via modulating the Hif-1α/Bnip3 axis in sepsis-induced myocardial dysfunction. International immunopharmacology, 2024 (PubMed: 37984253) [IF=4.8]

7). Regulation of P300 and HDAC1 on endoplasmic reticulum stress in isoniazid-induced HL-7702 hepatocyte injury. JOURNAL OF CELLULAR PHYSIOLOGY, 2019 (PubMed: 30786008) [IF=4.5]

Application: WB    Species: human    Sample: ADLI cell

FIGURE 5| Altered P300 and HDAC1 affect ERS in cells in ADLI. (a) The mRNA content of P300, HDAC1, GRP78, and CHOP in different groups after treatment with C646 and MS‐275 for 6 hr. (b) Western blot analysis and (c) gray value detection of P300, HDAC1, GRP78, and CHOP in different groups. Means ± SEM were calculated from six independent experiments. A one‐way ANOVA with SNK‐q test was performed.*p < 0.05 compared with the levels in the control group.

8). The P300-ARRDC3 axis participates in maternal subclinical hypothyroidism and is involved in abnormal hepatic insulin sensitivity in adult offspring. Heliyon, 2024 (PubMed: 39568856) [IF=4.0]

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.